11/1/2012 | CVLM | Human Genome sets 'increase period' for conversion of 3% notes
|
9/7/2012 | CVLM | Human Genome sets 'increase period' for conversion of 3% notes
|
8/3/2012 | CVLM | Human Genome announces dates for make-whole conversion period, put
|
8/1/2012 | CVLM | Human Genome announces put option, make-whole conversion adjustment
|
7/16/2012 | CV | Market Commentary: Human Genome mixed on takeout news; Alpha Natural down after stock downgrade; Regis adds
|
5/17/2012 | CV | Market Commentary: Dendreon declines after J&J drug news; Patriot Coal keeps sliding; Chesapeake lower again
|
5/9/2012 | CV | Market Commentary: Reoffered Annaly steady; Chiquita down after earnings; Human Genome unfazed by hostile bid
|
4/23/2012 | CV | Market Commentary: Central European Distribution jumps on investment; Amylin up; James River Coal plunges
|
4/20/2012 | CV | Market Commentary: SanDisk slides outright, adds on hedge; Chesapeake flat to lower; AMR adds on merger talk
|
4/19/2012 | CV | Market Commentary: Human Genome adds outright, slides on hedge; New Titan gains dollar neutral; Gilead mixed
|
4/4/2012 | CV | Market Commentary: SanDisk 1.5% convertibles come in on hedge; NetApp trades in line; Western Refining adds
|
2/7/2012 | CV | Market Commentary: Coinstar jumps after earnings, Verizon deal; Dendreon edges slightly higher after pop
|
1/25/2012 | CV | Market Commentary: Illumina 'rips' higher outright, expands on hedge; Life, Human Genome move in sympathy
|
1/12/2012 | CV | Market Commentary: Human Genome premium expands; new PHH extends gains; Petroplus, Sino-Forest in focus
|
12/30/2011 | CV | Outlook 2012: Convertibles primary market set for weakness without higher rates, stronger economy
|
11/15/2011 | CV | Market Commentary: Goldcorp active; Meritor, ViroPharma shed about a point on swap; Air Lease deal revised
|
11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
11/3/2011 | CV | Human Genome greenshoe exercise ups 3% convertibles to $494.5 million
|
11/3/2011 | CV | Market Commentary: Jefferies extends losses; New Human Genome paper flat dollar neutral; MGM adds premium
|
11/2/2011 | CV | New Issue: Human Genome sells upsized $430 million 3% seven-year convertibles at discount of 99
|
11/2/2011 | CV | Market Commentary: Human Genome's new $430 million deal prices at 99, edges higher; MF Global adds a little
|
11/2/2011 | CVLM | Human Genome may buy back 2.25% convertibles with new issue proceeds
|
10/24/2011 | CV | Market Commentary: Convertibles rise on light volume; Radian up; hedged players lose on RightNow's Oracle offer
|
10/21/2011 | CV | Market Commentary: SanDisk moves up on positive earnings; Old Nuance opens up; Investment-grade names active
|
10/5/2011 | CV | Market Commentary: Microsoft convertibles gain on reported Yahoo! bid; Hologic, Human Genome head upward
|
9/21/2011 | CV | Market Commentary: Medtronic wins patent case against NuVasive; Human Genome gains; Alpha pulls down coal
|
8/1/2011 | CVLM | Human Genome exchanges $77.53 million of 2.25% convertibles for stock
|
8/1/2011 | SP | New Issue: RBC prices $605,000 14% reverse convertibles linked to Human Genome
|
7/12/2011 | CV | Market Commentary: Convertibles fall; Europe fears build with Ireland's downgrade; volumes low amid volatility
|
3/14/2011 | SP | New Issue: RBC prices $630,000 15.22% reverse convertibles linked to Human Genome
|
11/11/2010 | CV | Market Commentary: Human Genome climbs on takeover hopes; DryShips takes off on stock upgrade; UAL higher
|
9/27/2010 | CV | Market Commentary: LDK paper jumps on new borrowing agreement; AirTran surges on merger deal; Newpark on tap
|
7/12/2010 | CV | Market Commentary: Transocean gains on Gulf progress; Human Genome, Microsoft up with market; Alcoa moves higher
|
7/9/2010 | CV | Market Commentary: Airline names higher; Xilinx, Sirius improve; Transocean strong; but Cheniere Energy falls
|
6/28/2010 | CV | Market Commentary: Convertibles mixed on light volume; Navistar better; ProLogis down in line; Cephalon adds
|
4/9/2010 | CV | Market Commentary: Convertibles action crimped by low vol., vacations; Cephalon, Human Genome gain; Ford off
|
3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
1/11/2010 | BWCV | Human Genome expects to end 2009 with $1.2 billion cash, investments
|
1/8/2010 | CV | Market Commentary: Convertibles secondary active; Titan, DryShips richen; PetroBakken sells $750 million deal
|
12/1/2009 | CV | Market Commentary: Convertibles action revives; gold names in focus; Energy XXI, Sino-Forest launch new deals
|
11/2/2009 | CV | Market Commentary: YRC jumps on exchange; Vornado up on tender; Human Genome surges on lupus drug; Ford to price
|
10/29/2009 | CVHY | Human Genome files automatic shelf covering stock, debt, preferreds
|
10/19/2009 | CV | Market Commentary: Lincare flat to higher, Steel Dynamics steady; GMX Resources, Forest City, Dole to price
|
9/14/2009 | CV | Market Commentary: PDL BioPharma, Human Genome in trade amid takeout talk; Magma finalizes exchange offer
|
8/26/2009 | CV | Market Commentary: Textron, International Game add; Transocean slips; Charming Shoppes gains in quiet tradee
|
8/25/2009 | CV | Market Commentary: Human Genome strengthens on takeover talk; AMD extends gains; Radio Shack marketed at 99.75
|
8/25/2009 | SS | Market Commentary: Human Genome stock up on deal talk; Venture OKs buyout bid; Syniverse likely off deal market
|
8/4/2009 | CV | Market Commentary: Hologic higher on earnings, forecast; Vale, Human Genome gain after upgrades; Onyx plans deal
|
7/27/2009 | CV | Sell Human Genome 2012 convertibles, buy 2011 issue, Barclays advises
|
7/24/2009 | CV | Market Commentary: Intel eyed as volume name; Ingersoll-Rand, Actuant strong; Human Genome gains more; Medarex over par
|
7/23/2009 | CV | Market Commentary: Earnings help convertibles extend strength; Ford gains on profit; OSI, Human Genome higher
|
7/20/2009 | CV | Market Commentary: Human Genome surges on lupus trial; Lincare trades before earnings; CIT busy; Intel to price
|
7/16/2009 | CV | Market Commentary: CIT preferred gets crushed, mandatory steady; Janus jumps on debut; Human Genome mostly quiet
|
6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
2/26/2009 | CV | Human Genome Sciences buys back $106.2 million of its 2.25% convertibles due 2011, 2012
|
2/6/2009 | CV | Market Commentary: Convertibles strengthen: shorter-dated paper adds 0.375 to 0.5 point; B of A surges; AMD gains
|
1/30/2009 | CV | Market Commentary: Alliant Techsystems active, little changed; financials ease amid uncertainty; Newmont extends gains
|
12/5/2008 | CV | Market Commentary: Nabors little changed on lower oil; GM, Ford mixed; Sinclair Broadcast for sale, but no buyers seen
|
12/1/2008 | CVHY | Human Genome Sciences files $400 million shelf registration
|
1/23/2008 | CV | Market Commentary: National City, Kinross Gold set to price, looking cheap; BofA bringing billions; Human Genome slashed
|
6/11/2007 | CV | Market Commentary: MannKind takes off; Molson quiet in gray; Human Genome rebounds; three REITs, Trex launch deals
|
11/16/2006 | BT | Human Genome keeps focus on Albuferon, LymphoStat-B, Abthrax
|
11/9/2006 | BT | JMP reiterates Human Genome at outperform
|
11/8/2006 | BT | Human Genome Sciences: net loss for the quarter improves, phase 3 trials planned by year end
|
11/8/2006 | BT | Merrill keeps Human Genome at buy
|
11/7/2006 | BT | Merrill keeps Human Genome at buy
|
11/1/2006 | BT | JMP keeps Human Genome at market outperform
|
10/5/2006 | BT | Human Genome kept at buy by Merrill
|
10/5/2006 | BT | JMP keeps Human Genome at market outperform
|
10/5/2006 | CV | Market Commentary: Forest City gains modestly on debut; HRPT upsizes deal; United Dominion prices; Human Genome climbs
|
9/18/2006 | CV | Market Commentary: XM Satellite maintains climb; Commonwealth climbs on takeover; Human Genome keeps tightening
|
9/12/2006 | BT | Human Genome keeps buy from Merrill
|
8/10/2006 | BT | Cephalon kept at neutral by Merrill
|
8/9/2006 | BT | Human Genome Sciences to begin phase 3 program for lupus drug LymphoStat-B this year
|
8/9/2006 | BT | Human Genome Sciences reports second-quarter net loss of $61.3 million
|
7/20/2006 | BT | Human Genome starts HGS-ETR1 trial in advanced multiple myeloma
|
6/27/2006 | BT | Human Genome reiterated at market outperform by JMP
|
6/22/2006 | BT | Human Genome's LymphoStat-B reduced lupus disease activity in phase 2 study
|
6/21/2006 | BT | Human Genome reiterated at market outperform by JMP
|
6/20/2006 | BT | Human Genome expects $165 million in revenues through ABthrax contract with U.S. government
|
6/20/2006 | BT | Market Commentary: Discovery Labs bounces; Biomira looks for acquisitions; Curis hits new low; Human Genome higher
|
6/19/2006 | BT | Human Genome reiterated at market outperform
|
6/12/2006 | BT | Human Genome Sciences establishes CoGenesys as independent company
|
6/8/2006 | BT | Merrill upgrades Human Genome to buy
|
6/7/2006 | BT | JMP reiterates Human Genome at market outperform
|
6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
6/6/2006 | BT | Human Genome to work with Novartis on Albuferon for potential $507.5 million in royalties
|
5/30/2006 | BT | JMP's Biotechnology Industry Overview
|
5/11/2006 | BT | Human Genome reiterated at market outperform
|
5/10/2006 | BT | Human Genome reports revenues up at $6.8 million
|
5/3/2006 | BT | Human Genome stays at neutral by Merrill
|
5/2/2006 | BT | Human Genome to raise $380 million in cash from real estate transactions
|
5/2/2006 | BT | JMP keeps Human Genome at market outperform
|
5/1/2006 | BT | Human Genome releases positive trial results for Albuferon, plans to seek higher-dose regimen
|
5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
4/27/2006 | BT | Market Commentary: Acadia sinks with stock float on deck; Human Genome gains 9%; Isis gains big on data; Ark rises
|
4/5/2006 | BT | Market Commentary: Allergan rolls out $700 million note; Discovery falls on FDA request for more data; Human Genome up
|
3/16/2006 | BT | JMP reiterates Human Genome at market outperform
|
3/15/2006 | BT | Human Genome kept at neutral by Merrill
|
3/15/2006 | CV | Market Commentary: Waste Connections gains on debut; Universal ups premium in talk; CSX, PMC-Sierra gain on upgrades
|
3/14/2006 | BT | Market Commentary: PharmAthene going public via Siga merger; Corautus crashes, deal nixed; Novavax, Generex up
|
3/14/2006 | CV | Market Commentary: Fair Isaac plunges on fears of new rival product; Human Genome slides on mixed trial results
|
3/14/2006 | BT | Human Genome announces interim results of phase 2b, phase 2 studies of Albuferon in hepatitis C
|
2/16/2006 | CV | Market Commentary: Amgen convertibles active in trade; Halliburton gains; XM Satellite lower
|
2/10/2006 | BT | Human Genome reiterated at market outperform by JMP
|
2/9/2006 | BT | Human Genome kept at neutral by Merrill
|
1/19/2006 | BT | Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
|
1/19/2006 | CV | Market Commentary: Advanced Micro, Cypress gain, but Intel weaker; Hutchinson prices upsized $225 million deal
|
1/11/2006 | BT | Merrill maintains Human Genome at neutral
|
1/10/2006 | BT | Human Genome gets $5 million milestone from GlaxoSmithKline for diabetes drug candidate
|
1/9/2006 | BT | Human Genome Sciences licenses gene to Amgen
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
1/9/2006 | CV | Market Commentary: Convertibles market extends gains; Human Genome, GM, Delta Air Lines, Duke up
|
12/14/2005 | BT | JMP says Human Genome still market outperform
|
12/14/2005 | BT | Market Commentary: BB Biotech deal on tap Friday; Amgen, Abgenix ink long-awaited merger; Oxigene seen on deck
|
12/14/2005 | BT | Human Genome maintained by Merrill at neutral
|
12/13/2005 | BT | Human Genome to spin off CoGenesys division
|
12/12/2005 | BT | Human Genome says phase 2 trial of HGS-ETR1 shows clinical responses for non-Hodgkin's lymphoma
|
11/21/2005 | BT | Merrill Lynch maintains Human Genome at neutral
|
11/18/2005 | BT | JMP reiterates Human Genome at market outperform
|
11/17/2005 | BT | Human Genome's LymphoStat-B shown to improve rheumatoid arthritis symptoms
|
11/17/2005 | BT | Human Genome says trials of HGS-ETR1 with chemo show promise in fighting advanced solid tumors
|
11/17/2005 | BT | Human Genome says two phase 1 studies show HGS-ETR2 stabilized disease of some refractory cancer patients
|
11/15/2005 | BT | Human Genome's Albuferon eliminated hepatitis C virus in 30% of patients, study says
|
11/11/2005 | BT | JMP maintains Human Genome at market outperform
|
11/9/2005 | CV | Market Commentary: Convertibles still weak, Blockbuster lower; but new issues heat up with $2 billion Prudential deal
|
11/8/2005 | CV | Human Genome Sciences to redeem 33/4%, 5% convertible notes due 2007
|
11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
11/1/2005 | BT | Human Genome Science study shows safety of HGS-ETR1, GlaxoSmithKline to co-develop
|
11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
10/27/2005 | BT | JMP keeps Human Genome at market outperform
|
10/25/2005 | BT | Human Genome begins phase 2b study for Albuferon
|
10/25/2005 | BT | Merrill Lynch maintains Human Genome at neutral
|
10/25/2005 | BTCV | Human Genome buys back $177.5 million in convertible notes
|
10/20/2005 | BT | Merrill Lynch initiates Human Genome at neutral
|
10/14/2005 | BT | Market Commentary: Predix, Electro-Optical IPOs imminent; Durect gains on trial news; Voyager IPO talk seen aggressive
|
10/13/2005 | BT | Market Commentary: Human Genome finds volatility players get it; Access Pharma off, then steadies; Endo, Noven firm
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|
10/6/2005 | BT | Market Commentary: Endo, Panacos mixed after deals; Invitrogen off; Oscient plunges; Human Genome continues spiral
|
10/6/2005 | BT | JMP keeps Human Genome at outperform, cuts target
|
10/5/2005 | BT | Market Commentary: Human Genome stock falls 29%, convertibles lose outright, up on swap; Vertex slides on profit taking
|
10/5/2005 | CV | Market Commentary: Human Genome, ADC drop outright; Mercury Interactive steady, shares lower; Freeport-McMoRan down
|
10/4/2005 | BT | Human Genome maintained by JMP at market outperform
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/20/2005 | BT | Human Genome kept by JMP at market outperform
|
9/19/2005 | CV | Market Commentary: CapitalSource jumps; GM, Ford, retail names weaken; two new deals launched
|
9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
8/18/2005 | BT | Human Genome Sciences at outperform by JMP
|
8/12/2005 | CV | Market Commentary: JDS Uniphase, Human Genome weaken in thinly traded convertibles market
|
8/5/2005 | CV | Market Commentary: LifePoint closes higher; Human Genome also gains, but automaker, REIT convertibles track lower
|
8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
8/4/2005 | CV | Market Commentary: Affordable Residential issue rises; Human Genome loses ground; LifePoint prices after the close
|
8/4/2005 | BTCV | New Issue: Human Genome prices $230 million seven-year convertibles to yield 2.25%, up 20%
|
8/3/2005 | CV | Human Genome to buy back 5%, 33/4% convertibles with new deal proceeds
|
8/3/2005 | BTCV | Human Genome to price $230 million of seven-year convertibles to yield 2.25%, up 20%
|
8/3/2005 | BT | Market Commentary: Lilly launches $1.5 billion floater; Human Genome $230 million convert at bat; MannKind taps PIPEs
|
8/3/2005 | CV | Market Commentary: Human Genome to price $230 million of convertibles; Reebok paper jumps on buyout news
|
7/26/2005 | BT | Human Genome estimates upped by JMP
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/26/2005 | CV | Market Commentary: GM up on GMAC financing; Ford, DaimlerChrysler mixed; Manor Care, Barnes at bat; Fairmont Hotels falls
|
7/11/2005 | CV | Market Commentary: Northwest Airlines spurs airlines convertibles; Schlumberger extends gains; but biotech, technology ease
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
3/21/2005 | CV | Human Genome files $400 million shelf
|
12/7/2004 | CV | Market Commentary: CMS new deal bid at issue; Dress Barn bid up 3.5 points; Seacor launches overnighter
|
10/19/2004 | CV | Human Genome Sciences buys back $218.1 million 33/4% convertibles, $60.1 million 5% convertibles
|
10/4/2004 | CV | Human Genome greenshoe partially exercised, raising convertibles to $280 million
|
9/30/2004 | CV | S&P rates Human Genome convertible CCC
|
9/29/2004 | CV | New Issue: Human Genome upsized $250 million convertible at 2.25%, up 40%
|
9/29/2004 | CV | Market Commentary: Human Genome straddles par; Calpine's issue falls 3 points; Charter off; United Rentals up
|
9/28/2004 | CV | Market Commentary: Human Genome up 1.5 in gray on tighter talk; Calpine, American Financial issues up; Lions Gate emerges
|
9/28/2004 | CV | Human Genome $200 million convertible talk amended to 2.25% yield, premium richened to 40% from 30%-35%
|
9/27/2004 | CV | Human Genome $200 million convertible talked at 2.25%-2.75% yield, up 30%-35%
|
9/27/2004 | CV | Market Commentary: Human Genome, American Financial deals emerge; new Calpine issue quiet; AtheroGenics soars after-hours
|
9/27/2004 | CV | Human Genome Sciences to buy back convertibles with $200 million offering proceeds
|
3/26/2004 | CV | S&P: Human Genome unaffected
|
1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
7/12/2002 | CV | Market Commentary: Market holds firm against dip in stocks as more buyers emerge
|
6/27/2002 | CV | Market Commentary: Market volatility creates trading opportunities; selling continues in telecom, spreads to media
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|